Potency Analysis of Medical Marijuana Products from New York State Lingyun Li, Bryan C. Duffy, Lorie A. Durocher, Mark A. Dittmar, Robert A. Acosta, Emily R. Delaney, Lei Li, Kenneth M. Aldous and David C. Spink Cannabis and Cannabinoid Research, Volume X, Number X, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0037 Abstract Introduction : In the United States, medicalmarijuana programs have been established in 29 states and the District of Columbia. In 2014, New York State (NYS) approved medical marijuana legislation, and its program became fully operational in January of 2016. Products manufactured under the auspices of the program may be used by certified patients in [...]
Lire la suiteLe Cannabidiol, l’autre canabinoïde présent dans le cannabis : une piste thérapeutique prometteuse? Traiter la dépendance avec du cannabidiol ? Si peu d’études ont pour l’heure été menées chez l’Homme, l’idée fait son chemin... et inspire les instigateurs d’une étude-pilote «CANNAVAP». Grégoire Cleirec et Pierre Poloméni Publié le 20 Mai 2019 par : Revue SWAPS n°90, "Du Cannabis Thérapeutique à la Régulation". http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891 L’Agence nationale de sécurité du médicament (ANSM) a annoncé récemment la création d’un comité scientifique spécialisé sur «l’évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France». Une façon de combler notre retard. À [...]
Lire la suiteRevue SWAPS n°90: Du Cannabis Thérapeutique à la Régulation, 1er trimestre 2019 EDITO S’agissant de la disponibilité du cannabis thérapeutique en France, la ministre de la santé, Agnès Buzyn, avait quelque peu entrouvert la porte : «C’est peut-être un retard que la France a pris quant à la recherche et au développement du cannabis médical. D’autres pays l’ont fait. (…) il n’y a aucune raison d’exclure, sous prétexte que c’est du cannabis, une molécule qui peut être intéressante pour le traitement de certaines douleurs très invalidantes». De fait, l’Agence nationale de sécurité du médicament (ANSM) a annoncé récemment (lire page 21) la [...]
Lire la suiteA role for cannabidiol in psychiatry? Keep calm and follow the drug development rules Gabriella Gobbi THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, VOL. 20, NO. 2, 98–100 Commentary https://doi.org/10.1080/15622975.2019.1584680 Along with tetrahydrocannabinol (THC), cannabidiol (CBD) is one of the main pharmacological components of Cannabis sativa and indica. Unlike THC, which binds CB1 receptors, CBD does not cause any dependence, and acts mostly via 5-HT1A and TPRV1 receptors (De Gregorio et al. 2018). Khoury et al. (2019) recently published a systematic review on the role of cannabidiol in psychiatry in the World Journal of Biological Psychiatry. After analysing 609 articles, they found six case reports, [...]
Lire la suiteEffects of Cannabidiol and a Novel Cannabidiol Analog against Tactile Allodynia in a Murine Model of Cisplatin-Induced Neuropathy: Enhanced Effects of Sub-Analgesic Doses of Morphine Hannah Marie Harris, Waseem Gul, Mahmoud A. ElSohly, Kenneth J. Sufka Medical Cannabis and Cannabinoids, 2018, 1, 54–59 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489077 Abstract Objective : This research examined whether a cannabidiol (CBD)-opioid pharmacotherapy could attenuate cisplatin-induced tactile allodynia. Methods : Mice (C57BL/6) were given 6 doses of 2.3 mg/kg cisplatin intraperitoneally (IP) on alternating days to induce tactile allodynia as quantified using an electric von Frey (eVF). Test groups in Experiment 1 received either vehicle, 0.1 [...]
Lire la suitePharmacokinetics and Tolerability of Δ9-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules for the Systemic Delivery of Δ9-THC Mahmoud A. ElSohly, Waseem Gul, Larry A. Walker Medical Cannabis and Cannabinoids, 2018, 1, 44–53 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489037 Abstract The objectives of this study were: (1) to assess the safety, tolerability, and pharmacokinetics of ascending doses of Δ9- tetrahydrocannabinol-hemisuccinate (THC-HS) after rectal administration as suppositories in male volunteers; and (2) to compare the pharmacokinetics of oral administration of Δ9-tetrahydrocannabinol (Δ9-THC) with an equivalent amount of Δ9-THC delivered as THC-HS via the suppository formulation. In support of the pharmacokinetic evaluations, [...]
Lire la suiteHuman Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations Pascale Meyer, Manuela Langos, Rudolf Brenneisen Medical Cannabis and Cannabinoids, 2018, 1, 36–43 Preclinical Science and Clinical Studies – Research Article DOI: 10.1159/000489034 Abstract Background : Due to variable absorption and extensive firstpass metabolism, the bioavailability of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is low, and, therefore, alternative application forms are necessary. Methods : In an open-label, 2-period phase-1 study on 11 healthy volunteers, a combination of THC and CBD was compared by pulmonary (inh) and intravenous (iv) application. The liquid aerosol was produced by an in vitro validated pressurized metered-dose inhaler (pMDI) device, releasing 41–44% [...]
Lire la suiteRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression : a randomized placebo-controlled trial Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias, Katia C. Andrade, Morgana M. Novaes, Jessica A. Pessoa, Sergio A. Mota-Rolim, Flávia L. Osório, Rafael Sanches, Rafael G. dos Santos, Luís Fernando Tófoli, Gabriela de Oliveira Silveira, Mauricio Yonamine7, Jordi Riba, Francisco R. Santos, Antonio A. Silva-Junior, João C. Alchieri10, Nicole L. Galvão-Coelho5,11, Bruno Lobão-Soares5,12, Jaime E. C. Hallak, Emerson Arcoverde, João P. Maia-de-Oliveira and Dráulio B. Araújo Psychological Medicine, June 2018, 1-9 https://www.cambridge.org/core doi.org/10.1017/S0033291718001356 Abstract Background. Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods. [...]
Lire la suite3rd International Medical Cannabis Conference (CannX 2018) Tel Aviv, Israël, October 14–16, 2018 Medical Cannabis and Cannabinoids, 2018, 1, 119–129 Published online : October 4, 2018 DOI: 10.1159/000493905 Abstracts CANNX18-0023 Co-Culture, Stigma and Deprivations among Medical Cannabis Patients in Israel H. Bonny-Noach Ariel University, Department of Criminology, Ariel, Israel CANNX18-0039 Cannabis Is Personal: The Intersection Between Human Genetics and Cannabis L. May, CEO & Founder of EndoCanna Health, Seattle, USA CANNX18-0046 Rationale to Evaluate Community-Led Interventions Employing Cannabis as Harm Reduction During the Opioid Overdose Crisis M.J. Milloy1, K. Heed2 1British Columbia Centre on Substance Use, Research, Vancouver, Canada; 2GrowX Global, Operations, Vancouver- BC, Canada CANNX18-0041 Concrete Evidence of Medical Cannabis Saving Lives and How Data Can Help [...]
Lire la suiteMedical Cannabis and Cannabinoids : An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? Magdalena Grill, Carina Hasenoehrl, Martin Storr, Rudolf Schicho Medical Cannabis and Cannabinoids, 2018, 1, 28–35 © 2018 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca DOI: 10.1159/000489036 Abstract : In the past few years, we have witnessed a surge of new reports dealing with the role of cannabinoids, synthetic as well as herbal, in the mechanisms of inflammation and carcinogenesis. However, despite the wealth of in vitro data and anecdotal reports, evidence that cannabinoids could act as beneficial drugs in inflammatory bowel disease (IBD) or in [...]
Lire la suite